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Inﬂammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is associated with enhanced leukocyte
inﬁltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte traﬃcking is a major target
forIBDtherapy.Pastandemergingtechniquestostudyleukocytetraﬃckingbothinvitroandinvivohaveexpandedourknowledge
of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and
integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there
is an abundance of preclinical data demonstrating eﬃcacy of leukocyte traﬃcking inhibitors, many have yet to be conﬁrmed in
clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.
1.Introduction
Leukocyte migration is fundamental to immunologic mobi-
lization in response to insult and injury. A coordinated series
of molecular events underpins the traﬃcking of lymphocytes
and granulocytes into stressed tissue with participation of
adhesion molecules, chemokines, and their receptors.
Theinﬂammatoryboweldiseases(IBDs),Crohn’sdisease
(CD) and ulcerative colitis (UC), are distinct syndromes, but
both are associated with enhanced leukocyte traﬃcking to
the inﬂamed gut. Thus, targeting the multistep leukocyte
adhesion cascade has been employed as a therapeutic
strategy. Here, we focus on the contribution of leukocyte
traﬃcking to the pathogenesis of IBD. An overview of
strategies employed to target leukocyte recruitment and of
emerging models used to test these targets is presented.
2. IBD
Crohn’s disease and ulcerative colitis are recurring, relapsing,
and remitting disorders characterized by chronic inﬂam-
mation of the intestinal mucosa. Though they share some
common clinical symptoms such as diarrhea and abdominal
pain, CD and UC possess very distinct features. Crohn’s dis-
ease manifests as a transmural inﬂammation that can poten-
tially develop anywhere along the gastrointestinal tract but
primarily occurs in the terminal ileum and proximal colon.
Ulcerations,granulomas,andbowelﬁstulasarecharacteristic
histopathological features. In contrast, ulcerative colitis
seldom ulcerates and is a relatively superﬁcial inﬂammation
of the mucosa that is diﬀuse, continuous, and restricted to
the colon, usually extending proximally from the rectum. It
is characterized by signiﬁcant goblet cell depletion and crypt
abscesses, but granuloma development is not a feature. In
both CD and UC, leukocyte inﬁltration into the inﬂamed
intestine is fundamental to disease development and perpet-
uation. The inﬁltrated eﬀector cells resist apoptosis and per-
sistently release harmful inﬂammatory cytokines causing tis-
suedamage.InCD,thecharacteristicgranulomasformupon
dense accumulation of activated T cells and macrophages.
Ulcerative colitis is characterized by excessive mucosal
inﬁltration of T cells and neutrophils, the latter forming
the characteristic crypt abscesses [1]. The pivotal role of T
cells, neutrophils, and their proinﬂammatory cytokines in
the pathogenesis of IBD has been reviewed elsewhere [2, 3].
Genetic and environmental risk factors have been impli-
catedinIBD(forreviewsseeXavierandPodolsky[1],Melgar
andShanahan[4],andChoandBrant[5]).Despiteextensive
research, current therapeutic options in IBD remain limited,
often varying in their maintenance, toxicity, and tolerability
[6–8]. Novel therapeutic strategies for IBD are needed.2 Clinical and Developmental Immunology
3.LeukocyteTrafﬁcking
3.1. In Vitro and In Vivo Models of Leukocyte Traﬃcking
3.1.1.TraditionalMethods. Theconceptoflymphocyterecir-
culation and homing was ﬁrst demonstrated by Gowans
and Knight in 1964, when they followed the migration of
radiolabeled lymphocytes in rats using autoradiography and
scintography [9]. They and others found that while na¨ ıve
lymphocytes migrated to all secondary lymphoid tissues,
activated lymphocytes preferentially migrated back to the
tissueinwhichtheyhadbeenexposedtotheantigen.Inorder
to devise rational therapeutic strategies that target leukocyte
migration, it is important to elucidate leukocyte traﬃcking
patterns in vivo. Techniques employed to study leukocyte
traﬃcking frequently involve ex vivo labeling of donor cells
and adoptive transfer into recipient animals. Subsequently,
the distribution of the labeled cell population in recipient
tissues is assessed using a variety of imaging methods, such
as histological analysis of ﬁxed tissues. This technique has
provided us with valuable mechanistic knowledge, but it
does not permit direct examination of dynamic processes at
single-cell level or provide temporal or spatial information
within the physiological environment of lymphoid tissues.
Furthermore, labeling of cells ex vivo has been associated
with variable labeling eﬃciency, alteration of cellular func-
tions, and label elution postadoptive transfer. Radiolabeling
techniques, such as white cell scintigraphy, have been used
to successfully study neutrophil migration in clinical IBD
studies [10]. However, such methods are hampered by
radioactive decay, poor resolution, and cellular toxicity [11].
Myeloperoxidase (MPO) assays are commonly used to study
neutrophils and quantitate neutrophil inﬂux, but they do
not distinguish between neutrophils and macrophages and
can be problematic to carry out. Similarly, while in vitro
chemotaxis assays are regularly employed to analyze the
eﬀects of potential inhibitors on cell migration, there is no
guarantee that the cells will respond in the same way to the
test compound in vivo. Multiphoton intravital microscopy
has been widely used to image the dynamic movement
of lymphocytes by tracking ﬂuorescently labeled cells in
exposed or explanted lymph nodes (LNs) of living animals.
This technique has provided valuable insights into the
dynamics of T- and B-cell homing to LNs [12, 13]a n da l l o w s
single-cell tracking, in conjunction with high-resolution
images. Nonetheless, intravital microscopy is an invasive
technique, and the surgery required may interfere with the
ﬂ o wo fb l o o da n dl y m p hc r e a t i n ge x p e r i m e n t a la r t i f a c t s .
3.1.2. Molecular Imaging Techniques. Molecular imaging is
deﬁned as “the visualization, characterization and measure-
ment of biological processes at the molecular and cellular
levels in humans and other living systems” [14]. Over the
past decade, a number of such techniques have been adapted
to small animal imaging, oﬀering dynamic imaging methods
to localize leukocytes in vivo. Positron emission tomog-
raphy (PET) [15] and single-photon emission-computed
tomography (SPECT) [16, 17] use scintillation cameras
and other devices to detect radioactive emission from
radiolabeled cells within the body. Though these nuclear
imaging methods have excellent tissue penetration and cell
quantitation capability, they too are subject to the drawbacks
associated with radiotracers and exogenous labeling of cells.
Magnetic resonance imaging (MRI), which relies on the
nuclear resonance of protons in tissues upon scanning with
radio frequency radiation, has shown great promise to track
the recruitment of, for example, antigen-speciﬁc CD8+ T
cellstotargettumorsinvivo[18].However,thetimerequired
for imaging using this technique makes it unsuitable for
tracking fast-moving cells [19]. The substantial expense
of MRI and its relatively poor sensitivity and quantitative
capability have also hindered its use as a basic research tool.
Optical ﬂuorescence imaging has been frequently used to
t r a c kTc e l l sa n dh a sp r o v i d e du sw i t hi n v a l u a b l ed a t ao n
their migration patterns. The pitfalls with using ﬂuorescent
labels, such as CFSE and GFP, include signal loss due to
label dilution upon cell division and limited sensitivity and
speciﬁcity due to endogenous tissue autoﬂuorescence and
light scattering and absorption [20].
3.1.3. Bioluminescence Imaging. To illuminate cell traﬃcking
in vivo and to test speciﬁc inhibitors of this migration, we
used bioluminescence imaging (BLI) technology [21–23].
This form of optical imaging has several advantages over
other techniques for tracking cell migration. It eliminates the
necessity to prelabel cells, avoiding problems with exogenous
cell labeling. It allows direct in vivo and ex vivo visualization,
with no further processing of tissues required, and is, there-
fore, a less complicated and less labor intensive technique
than most other in vitro/ex vivo methods. Unlike other
molecular imaging methods, BLI combines high sensitivity
with relatively low cost while providing quantitative, spatial,
and temporal data. However, this technology has limitations.
Sincelighttransmissionthroughanimaltissuesiswavelength
dependent, loss of photon signal can occur with tissue
depth and light sources closer to the surface of the animal
can appear brighter. In addition, validation of potential
therapeutics using BLI should be carried out in conjunction
with in vitro mechanistic assays and in vivo eﬃcacy studies.
BLI has successfully monitored traﬃcking of bone marrow
mononuclear cells in ischemic myocardium [24] and CD4+
T cells in an experimental model of multiple sclerosis (MS)
[25]. These and other studies have shown robust and reli-
able correlation between cell numbers and bioluminescence
signals. We employed BLI to track both neutrophils and
lymphocytes inmurine models ofexperimental colitis andto
test potential inhibitors of their migration Figure 2 [21, 22].
3.2. The Leukocyte Traﬃcking Cascade
3.2.1. Selectins, Integrins, and Their Ligands. Circulating
leukocytes are subjected to extreme conditions with the ﬂow
of blood exerting a shearing stress on the cells dislodging
any that touch the vascular wall. To leave the circula-
tion and home to speciﬁc tissues, leukocytes must engage
several adhesion pathways involving intimate interaction
with endothelial cells [26]. Whether during physiological
recirculation or inﬂammatory conditions, the mechanismsClinical and Developmental Immunology 3
involved in leukocyte traﬃcking are eﬀectively the same.
The leukocyte traﬃcking cascade is depicted in Figure 1.
Leukocyte recruitment begins with tethering and rolling
of the cells along the microvascular endothelium via three
selectins: L-selectin, expressed by leukocytes, and E-selectin
and P-selectin, expressed by inﬂamed endothelial cells on
the blood vessel wall [27]. The ligand P-selectin glycoprotein
ligand-1 (PSGL-1) binds all three selectins and plays an
importantroleinleukocyterecruitmentunderinﬂammatory
conditions [28]. L-selectin is constitutively present on T cells
and interacts with its counter receptors, peripheral lymph
node addressin (PNAd) and mucosal addressin cell adhesion
molecule (MAdCAM)-1, acting as a mechanical anchor or
tether to the high endothelial venules (HEVs). This allows
the lymphocytes to roll along the vascular lining at a much
slower pace than erythrocytes. Selectins engage rapidly and
form strong bonds to secure contact. These bonds allow
chemokines and their ligands to transmit activating signals
for the next step in the migration cascade. Targeting selectins
and their ligands as a treatment strategy for inﬂammatory
disorders has been reviewed elsewhere [29].
Selectin bonds are unable to arrest cells at the vessel wall.
Firm leukocyte adhesion is achieved through bonds formed
downstream by the secondary adhesion molecules, integrins.
Integrins are diversely expressed on diﬀerent leukocyte
subpopulations and are composed of noncovalently linked
α and β chains. The α4 integrins, α4β1 and α4β7, play a
regulatory role in lymphocyte homing and recruitment to
inﬂammatory tissues, particularly to the inﬂamed intestine.
Two decades ago, it was revealed that memory T cells
from the gut preferentially homed to the gut [30]. This
phenomenon is linked to the expression of unique adhesion
molecules within the mucosa [31, 32]. Both α4β1 and
α4β7 are expressed by lymphocytes that reside in the gut
and gut-associated lymphoid tissues (GALTs), and their
respective ligands vascular cell adhesion molecule (VCAM)-
1 and MAdCAM-1 are expressed within the HEV’s in Peyer’s
patches (PPs) and the ﬂat-welled venules of the lamina
propria [33]. While the α4β7-MAdCAM-1 interaction is
restricted to leukocyte traﬃcking to the gut and GALT, the
α4β1-VCAM-1 pathway can also mediate leukocyte homing
to the central nervous system, speciﬁcally to the inﬂamed
brain [34]. Interestingly, mice deﬁcient in the β7 integrin
gene are unable to form proper PPs and possess decreased
numbers of lamina propria CD4+ Tc e l l sa n dBc e l l s[ 35].
The β2 integrins are also prominent participants in leukocyte
traﬃcking, mediating ﬁrm adhesion, particularly in the case
of neutrophils [36]. The β2 integrin lymphocyte function-
associated antigen (LFA)-1 is predominantly expressed by
lymphocytes and neutrophils and binds to its endothelial
cell ligands intercellular adhesion molecule (ICAM)-1 and
ICAM-2. In addition to leukocyte arrest, integrins can par-
ticipateinleukocyterolling.Underinﬂammatoryconditions,
lymphocytes can skip the selectin-mediated phase and bind
directly to endothelial cells via α4β7 [37].
Abundant evidence reveals that IBD is associated with
enhanced leukocyte traﬃcking to the gut mucosa and
altered expression of adhesion molecules [38]. Cytokines
such as interleukin (IL)-1β,I L - 6 ,a n dT N F - α,p r o d u c e d
upon stimulation of innate immune cells at inﬂammatory
sites [39], upregulate adhesion molecules and chemokines,
enhance leukocyte recruitment, and amplify the inﬂamma-
tory cascade. Expression of MAdCAM-1 is upregulated in
animal models of colitis [40, 41] and in active IBD [42–
44]. ICAM-1 and LFA-1 have also been implicated in a
number of experimental animal models of IBD [45, 46]. The
importance of adhesion molecules in IBD is evident from
preclinical colitis studies, where their blockade ameliorated
disease severity [47]. Table 1 summarizes preclinical and
clinical data reported so far. Similar results have been
reported in animal models of autoimmune disease including
MS and rheumatoid arthritis [48].
3.2.2. Chemokines and Their Receptors. Chemokines mediate
cell migration under normal physiological conditions and
leukocyte recruitment to tissues during innate and adaptive
immune responses. These small heparin-binding proteins
come from a diverse family that is classiﬁed into four major
subfamilies, CC, CXC, C, and CX3C ,b a s e do ns t r u c t u r a la n d
functional diﬀerences. The two most important subgroups
in terms of leukocyte traﬃcking to inﬂamed tissues are the
CC chemokines for dendritic cell (DC) and lymphocyte
recruitment and the CXC chemokines for recruitment of
neutrophils and monocytes. Chemokines exert their bio-
logical eﬀects on target cells by binding to speciﬁc G-
protein-coupled transmembrane receptors (GPCRs) on the
cell surface and activating an intracellular signaling cascade.
Consequently, an activating signal is sent to the integrin
switching it into a high-aﬃnity/high-avidity state so that the
rolling leukocyte can arrest itself and ﬁrmly adhere to the
HEVs, a step which is essential for leukocyte extravasation
into the target tissue [74]. For example, binding of CCR7
on na¨ ıve T cells to its chemokine ligand CCL21 on HEVs in
turn activates binding of α4β7 and LFA-1 to their endothelial
ligands MAdCAM-1 and ICAM-1, respectively [38]. In addi-
tion, the combined expression of chemokine receptors and
adhesion molecules by na¨ ıve and memory T lymphocytes
governtheir selective homing patterns. For instance,whileL-
selectin and CCR7 regulate na¨ ıve T-cell migration to periph-
eral LNs, expression of α4β7 in conjunction with CCR9
allows T-cell migration to the skin and gut. The encounter
between CCR7 and its ligands CCL19 and CCL21 bridges
the gap between innate and adaptive immune responses. Up-
regulation of CCR7 on antigen-laden DCs facilitates their
migrationintoLNsforT-cellpriming.Inaddition,enhanced
expression and binding of CCR7 on na¨ ıve T cells to CCL19
on DCs and CCL21 on HEVs mediate transmigration from
peripheral tissues into LNs. In contrast, downregulation
of CCR7 allows activated T cells to exit the LN area and
migrate to target tissues to carry out eﬀector functions
[75, 76]. Furthermore, elevated expression of CXCR5, the
ligand of CXCL13, on certain CD4+ T cells directs their
migration to the follicle to provide B-cell help [77]. Upreg-
ulated mucosal expression of numerous chemokines and
their counter receptors including CXCL8 (IL-8)/CXCR2,
CXCL9,10,11/CXCR3, CCL25/CCR9, CCL19,21/CCR7, and
CCL20/CCR6 is evident in active IBD and in models of
colitis [78–80]. Thus, chemokines orchestrate the activation,4 Clinical and Developmental Immunology
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Figure 1: Schematic view of the leukocyte traﬃcking adhesion cascade in IBD. Leukocytes tether and roll along the vascular endothelium via
selectin-mediated adhesion. They are then activated by chemokines into a high avidity, high aﬃnity state so that integrin-mediated strong
adhesion and arrest can take place. This prepares the leukocyte for transmigration through the blood vessel wall into the inﬂamed colon.
Chemokine activation can be inhibited by various chemokine/chemokine receptor inhibitors such as the CCR9 small molecule antagonist
Traﬁcet-EN, a monoclonal antibody to CXCR3 or a CXCR2 antagonist (shown in blue). Additionally, antagonists of integrin ﬁrm adhesion
include the anti- α4 integrin monoclonal antibody Natalizumab, the selective α4β7 small molecule antagonist MLN-02 and the antisense
intercellular adhesion molecule-1 (ICAM-1) oligonucleotide Alicaforsen (shown in blue). KO, knock out; LFA-1, Lymphocyte function-
associated antigen 1; MadCAM-1, mucosal addressin-cell adhesion molecule 1; PNAd, Peripheral lymph node addressin; RBC, red blood
cell; V-CAM-1, vascular-cell adhesion molecule 1.
recruitment, and retention of leukocytes, and, the more
insight we gain into their vital role, the more attractive they
become as potential therapeutic targets.
3.2.3. The Role of DCs in Lymphocyte Homing to the Gut.
The speciﬁc homing receptors expressed by activated T cells
are determined by DCs. Several murine studies show that
DCs from mesenteric lymph nodes (MLNs) or PPs imprint
gut tropism on antigen-experienced T cells, by inducing
expression of the gut homing receptors α4β7 and CCR9 [81–
83]. In the “steady state” mouse intestine, the ability to
confer gut homing speciﬁcity is restricted to the CD103+
intestinal DC subset [84–86]. The vitamin A metabolite
retinoic acid (RA) plays a central role in the process of
DC imprinting within lymphoid tissues. For instance, mice
deﬁcient in vitamin A have decreased numbers of T cells in
the intestine [37, 87, 88]. However, the dependency of DC-
T-cell imprinting on retinoic acid receptor (RAR) signaling
is complex and not yet fully characterized [89]. Also, the key
factors that induce DC imprinting activity have yet to be
identiﬁed; for example, germ-free studies have indicated that
gut bacteria are not required for intestinal DC imprinting of
α4β7 expression [90]. The speciﬁc role played by intestinal
DC imprinting in IBD remains elusive, but presumably
it inﬂuences the increased numbers of α4β+
7 and CCR9+
lymphocytes evident in the inﬂamed intestine [91]. Since
the CD103+ intestinal DC subset favors the generation of
Foxp3+ T-regulatory cells (Tregs) over Th17 cells, via a TGF-
β- and RA-dependent mechanism [92], targeting leukocyte
traﬃcking at the DC imprinting level may represent a
potential therapeutic strategy for IBD. Notably, a diet low in
vitamin A protects against colitis in mice, and this protection
is associated with increased levels of Tregs in the gut mucosa.
In this case, the reduced availability of RAR ligands aﬀects
lymphocyte homing to the gut by decreasing entry of α4β7
and CCR9+ T cells in favor of Tregs [93].Clinical and Developmental Immunology 5
Table 1: Targeting leukocyte traﬃcking in inﬂammatory bowel disease.
Target Drug type Preclinical eﬃcacy Therapeutic Clinical eﬃcacy
Adhesion molecules
α4 Integrins/ligands
Antisense MAdCAM-
1 oligonucleotide TNBS colitis [49, 50]
Natalizumab
(humanized IgG4 mAb
anti-α4 integrin)
CD (Phase IV) [51, 52] Prevented relapse,
induced remission
Anti-VCAM-1 mAb UC [53] Pilot study
Anti-MAdCAM-1
mAb DSS colitis [54, 55]
AJM300 (orally
available anti-α4
integrin mAB)
CD (Phase II) [56]
Reduced disease
activity, good
safety proﬁle
Small molecule α4
integrin antagonist DSS colitis [22]
Anti-β7 and
anti-MAdCAM-1
mAb
T-cell transfer colitis
[57]
Vedolizumab/MLN-02
(humanized IgG4 mAb
α4β7 integrin)
CD [58],
UC Phase II [59, 60]
Induced clinical
response and
remission, good
safety proﬁle
Anti-MAdCAM-1
mAb SAMP1/Yit mice [61]
Anti-α4β7 mAb Cotton top tamarin
model [62]
ICAM-1/LFA-1
Anti-ICAM-1 mAb
Antisense ICAM-1
oligonucleotide
DSS colitis [63, 64]
Alicaforsen (ISIS2303)
(antisense ICAM-1
oligonucleotide)
UC (Phase II) [65, 66]
Reduced disease
activity, good
safety proﬁle
Anti-ICAM-1 mAb SAMP1/Yit mice [67]
Chemokines
CCR9/CCL25
Anti-CCR9/CCL25
mAb Traﬁcet-EN
(CCX282-B)
SAMP1/Yit mice [68]
TNF (DeltaARE)
mice [69]
Traﬁcet-EN/CCX282-B
(small molecule CCR9
antagonist)
CD (Phase III) [70]
Induced clinical
remission, good
safety proﬁle
CXCR3/CXCL10 Anti-CXCL10 mAb I L - 1 0K O[ 71, 72]
DSS colitis [73]
MDX-1100 (humanized
anti-CXCL10 mAb) UC (Phase II) NCT00295282
NCT00656890
CD: Crohn’s disease; DSS: dextran sodium sulphate; ICAM-1: intercellular adhesion molecule 1; MadCAM: mucosal addressin-cell adhesion molecule 1;
senescence accelerated mice (SAMP1/Yit); TNBS: trinitrobenzene sulfonic acid; UC: ulcerative colitis; V-CAM-1: vascular-cell adhesion molecule1 .
3.2.4.S1PandControlofLeukocyteEgressfromTissues. While
chemokines control na¨ ıve T-cell migration to and within
LNs, the natural bioactive lipid sphingosine-1-phosphate
(S1P) regulates lymphocyte egress. S1P is formed upon
the phosphorylation of sphingosine by sphingosine kinase
and mediates a number of fundamental biological events
including endothelial barrier enhancement, lymphocyte dif-
ferentiation and immune cell traﬃcking [94]. Levels of S1P
in the blood and lymph are constitutively high while they are
low in tissues, increasing substantially upon inﬂammation.
Although synthesized in most cells, tissue levels of S1P are
tightly controlled due to intracellular degradation by S1P
lyase or phosphorylation by S1P phosphatases. Five S1P
receptors have been described so far, S1PR1–5, and are
expressed in a cell-type speciﬁc manner within diﬀerent
tissues [95]. S1PR1–3 are ubiquitously expressed in mam-
mals [96], while S1PR4 expression is restricted to lymphoid
tissues [97] and lung, and S1PR5 to brain, skin, and natural
killer (NK) cells [98]. The S1P/S1PR1 axis is essential for
lymphocyte egress from the thymus and spleen into the
blood and from the LNs into the lymph [99]. During
T-cell priming, elevated expression of CD69 on activated
lymphocytes promotes the temporary downregulation of
S1PR1expressiononthecellmembrane,disablingligationto
S1P and consequently trapping them within the LNs [100].
Concurrent binding of CCR7 to its ligand CCL21 mediates
competitive retention signals. Following clonal expansion,
CCR7 expression is lost and S1PR1 expression is upregulated
onceagain,allowingtheeﬀectorTcellstoleavethelymphoid
tissues, reenter the systemic circulation, and rapidly migrate
to sites of inﬂammation [101]. The S1P/S1PR interaction
alsoregulatesthemovementofDCs[102],neutrophils[103],
and NK cells [104]. S1P signaling and functions in immunity
have been reviewed elsewhere [105].
The discovery that the S1P/S1PR1 axis is essential for
lymphocyte egress added a new potential target for blocking
leukocyte migration in inﬂammatory diseases. Disruption of
this S1P gradient has been reported in numerous inﬂamma-
tory and/or autoimmune disorders including asthma [106]
and rheumatoid arthritis [107]. The novel immunosuppres-
sant FTY720 (Fingolimod) [108] is structurally similar to
S1PandposesasanS1Panalog.LikeS1P,itisphosphorylated
invivoandbindswithhighaﬃnityto4ofthe5S1Preceptors
S1PR1, S1PR3, S1PR4, and S1PR5 [109]. FTY720 interferes
with S1P signaling and blocks the response of lymphocytes
to egress signals from the lymphoid organs, sequestering
them within the LNs and PPs. The result is a rapid and
dramatic peripheral blood lymphopenia with depletion of6 Clinical and Developmental Immunology
circulating T and B cells. In contrast, FTY720 increases the
number of DCs in the blood and simultaneously reduces
their numbers in secondary lymphoid organs. In addition,
it can modulate DC cytokine signaling potentially aﬀecting
T-cell responses [110]. The mechanism of action of FTY720
is complex, and it is currently unclear whether it acts as an
agonist or functional antagonist or both during regulation
of lymphocyte recirculation in vivo. Since FTY720 inhibits
cell migration to inﬂammatory sites, it has shown great
potential as a treatment for inﬂammatory disorders [108].
In clinical studies, FTY720 successfully prevented kidney
transplant rejection [111–114] and proved highly eﬀective
in treating MS. It was recently approved by the US Food
and Drug Administration (FDA) as a ﬁrst-line treatment for
relapsing forms of MS. In terms of IBD, FTY720 ameliorated
experimental colitis arising as a result of chemical induction
[115–117], T-cell transfer [118], and IL-10 deﬁciency [119],
suggesting it may be a potential candidate for IBD treatment.
H o w e v e r ,r e p o r t so fs i d ee ﬀects such as bradycardia and
increased susceptibility to opportunistic infections [108]
dictate that the use of FTY720 therapeutically should be
approached with caution and that perhaps using more
selective drugs to target the S1P receptor pathway may be a
safer option and yield less side eﬀects. Indeed, the speciﬁc
agonist of S1PR1, SEW2871, has shown promise in preclin-
ical kidney transplantation studies [120] and exhibited anti-
inﬂammatory eﬀects in mice administered TNF-α [121]. In
addition, another selective S1PR1 agonist KRP-203 showed
therapeutic potential in IL-10-deﬁcient mice [122].
4. Preclinicaland ClinicalEvidenceof
TargetingAdhesion Molecules
Figure 1 and Table 1 summarize the data presented under
Sections 4 and 5.
4.1. Natalizumab. Promising preclinical data [22, 49, 50, 54,
55, 57, 61, 62] (also see Table 1)l e dt ot h eu s eo fh u m a n i z e d
α4 integrin antibodies in clinical trials. The most well-known
anti-α4 drug is Natalizumab (Tysabri), a humanized pan-
α4 monoclonal antibody. Natalizumab blocks the ability
of α4β1 and α4β7 to bind to their respective ligands on
the endothelium, preventing lymphocyte transendothelial
migration. This α4 antagonist was approved by the FDA in
2004 and is highly eﬀective in treating the symptoms of MS
[123, 124] and in preventing relapse and increasing remis-
sion rates in suﬀerers with moderate to severe CD [51, 52].
Natalizumab therapy has been associated with cases of pro-
gressive multifocal leukoencephalopathy (PML) in a small
number of patients, which is induced by the JC virus, an
opportunisticinfectionofthebrain[125].Thoughrare,PML
is a serious and often fatal disease. The approval and relative
success of Natalizumab have heightened interest and greatly
encouraged further research into targeting integrins and
their counter adhesion molecule ligands as a novel treatment
strategy for chronic inﬂammatory diseases, including IBD.
4.2. MLN-02. Vedolizumab (MLN-02) is a recombinant
humanized IgG1 monoclonal antibody selective for the
gut-speciﬁc integrin α4β7. By binding to α4β7, MLN-02
inhibits the adhesion and migration of leukocytes into the
gastrointestinal tract, preventing intestinal inﬂammation.
MLN-02 treatment ameliorated disease in the cotton top
tamarin model of colitis [126]a n ds a f e l ya n de ﬀectively
induced clinical response and remission in two double-
blinded placebo-controlled clinical trials of patients with
acti v eC Da n dU C[ 58–60]. The selectivity of MLN-02 makes
itlesslikelytoimpairsystemicimmunity andmoreattractive
as a therapeutic target for IBD.
4.3. Alicaforsen- (ISIS2302-) and LFA-1-Targeting Drugs.
Alicaforsen, a human ICAM-1 antisense oligonucleotide,
inhibits ICAM-1 production preventing T-cell adhesion,
extravasation, and subsequent migration to inﬂamed areas
[127]. Blocking ICAM-1 ameliorated colitis in a number
of preclinical models [63, 64, 67]. In clinical studies, this
approach has had variable success and in general has yielded
disappointing results in the treatment of CD [128–130].
However, there have been promising results with an enema
formulation of Alicaforsen in the treatment of UC [65]
and refractory pouchitis [131]. Efalizumab, a humanized
monoclonal IgG1 antibody treatment for plaque psoriasis, is
FDA approved and also acts by blocking the LFA-1/ICAM-
1 interaction. By doing this it inhibits T-cell migration to
the inﬂamed dermal and epidermal tissues. However, similar
to Natalizumab, serious adverse eﬀects, such as the Epstein-
Barr virus-associated B-cell lymphoma development, were
reported following treatment [132].
4.4. Small Molecule Antagonists. The immunogenicity of
antibody therapies has increased research into the use of
nonpeptide small molecule antagonists to block leukocyte
traﬃcking. Such therapeutics are less likely to elicit the
undesirable and serious immunogenic responses associated
with monoclonal antibody therapy, and, unlike antibodies,
theycanbetakenorallyandarelessexpensivetoproduce.We
analyzed the leukocyte traﬃcking blockade eﬀect of a small
molecule α4 integrin antagonist in a preclinical model of
IBD.Weconﬁrmedthetherapeuticeﬃcacyof thecompound
indextransodiumsulphate-(DSS-)inducedacutecolitisand
demonstrated its ability to inhibit leukocyte traﬃcking to the
inﬂamed gastrointestinal tract in vivo using bioluminescence
imaging, as shown in Figure 2 [22]. Previous studies using
small molecule integrin antagonists in other models of
inﬂammatory disease have also shown promising results
[133, 134].
5. Preclinicaland ClinicalEvidenceof
TargetingChemokines
5.1. CCR9. The chemokine CCR9 is exclusively expressed
by gut homing leukocytes and interaction with its counter
ligand CCL25 is essential for T-cell homing to the small
intestine [135]. The CCR9/CCL25 interaction speciﬁcally
contributes to the pathophysiology of small bowel CD [136].
Antibody blockade of this interaction reduced inﬂammation
in early stages of chronic ileitis in senescence acceleratedClinical and Developmental Immunology 7
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Figure 2: Inhibition of leukocyte migration by an α4 integrin antagonist in experimental colitis. Leukocytes were isolated from mesenteric
lymph nodes (MLNs) of β-actin luciferase mice and injected into recipient mice with dextran sodium sulphate- (DSS-) induced colitis.
The recipient mice received vehicle or α4 antagonist, 1 hour pre cell transfer. Whole body and organs ex vivo (colon and small intestine)
were imaged using an IVIS 100 charge-coupled device imaging system 4 hours following transfer. The pseudocolored images represent light
intensity, where red is the strongest, and violet is the weakest signal. Inhibition is detected in the colon and in Peyer’s patches of the α4
antagonist-treated mice.
(SAMP1/Yit) mice [68]. Additionally, pre- or post admin-
istration of a small molecule CCR9 antagonist (CCX282-
B/Traﬁcet-EN) reduced gut inﬂammation in TNFΔARE
mice, an experimental model of CD [69]. Interestingly,
Wermers et al. recently demonstrated that blockade of
CCR9 exacerbated chronic ileitis in these mice, by inhibiting
recruitment of Tregs to the small intestinal lamina propria
and MLNs [137]. The exact role of CCR9/CCL25 in large
intestinal inﬂammation remains unclear, and studies have
yielded conﬂicting results. Preliminary clinical data using
Traﬁcet-EN demonstrated a beneﬁcial therapeutic eﬀect in
both patients with ileal and colonic CD, by signiﬁcantly
reducing proinﬂammatory cytokine levels and disease scores
and maintaining clinical remission [70]. This is surprising,
since there is little or no expression of CCL25 in the colon
[138, 139]. However, recent data showed that, although
colonic levels of CCL25 are low in healthy mice, they
are signiﬁcantly upregulated upon DSS-induced colitis. In
addition, CCR9 knock-out (KO) mice with acute DSS colitis
exhibit enhanced severity of clinical symptoms and tissue
injury and display delayed recovery. Exacerbation of disease
was associated with an imbalance in DC subpopulations
and increased macrophage inﬁltration into the colon [138].
These data suggest that use of CCR9 blockade therapy in, for
example, strictly colonic UC, could have detrimental eﬀects.
5.2. CXCR3. CXCR3 is expressed by monocytes, T cells,
and NK cells and can mediate their recruitment to inﬂam-
matory sites by binding to its ligands CXCL9, CXCL10,
and CXCL11. CXCR3 engagement with these chemokines
mediates the rapid arrest of eﬀector T cells in vitro [140]a n d
selectively mobilizes high-CXCR3-expressing Th1 cells to
sites of mucosal inﬂammation [141]. Expression of CXCR3
and its chemokine ligands is elevated in both preclinical
and clinical models of IBD [142]. CXCL10 is considered
the most crucial and potent chemokine in CXCR3-mediated
chemotaxis, as it is highly upregulated and its expression
robustly correlates with disease severity in inﬂammatory
disorders such as IBD, MS, and arthritis [143–145]. More-
over, the ability of CXCL10 to preferentially attract Th1
cells emphasizes its contribution to these diseases [146].
CXCL10antagonismpreventedoramelioratedinﬂammation
in numerous preclinical models of inﬂammatory disease
[142]. More speciﬁcally, neutralization of CXCL10 using
monoclonal antibody therapy proved eﬀective in various
experimental models of IBD [71–73]. In contrast, in a
more recent study, though antibody blockade of CXCL10
reduced intestinal epithelial cell proliferation and CXCR3+
cell migration in vitro and in vivo, it had no signiﬁcant
eﬀect on disease in several preclinical models including IBD,
arthritis, and MS [147]. The reasons for the discrepancies
between these studies are unclear, but diﬀering methods
of antagonism and disease induction may play a part. For
instance, Byrne et al. used T-cell (CD4+CD45RBHi)t r a n s f e r
to induce colitis, while earlier studies employed the IL-10KO
and DSS-induced colitis models. Future clinical trials are
likely to resolve these uncertainties (NCT01294410).
5.3. CXCR2. Since neutrophil inﬂux into the intestinal
mucosa and resulting tissue damage is a major characteristic
of active IBD, especially UC, neutrophil-speciﬁc chemokine
receptors, and their ligands also represent potential ther-
apeutics. Neutrophils exclusively use integrins of the β2
family to arrest on the endothelium and antibodies against8 Clinical and Developmental Immunology
these integrins reduced tissue damage in experimental colitis
[148]. Engagement of the chemokines human IL-8/CXCL8
and the murine functional homologs CXCL1 and CXCL2
with their receptors CXCR1 and CXCR2 triggers numerous
signal transduction cascades, which in turn activate neu-
trophil recruitment to target tissues [149]. Inﬂammatory
mediators such as bacterial lipopolysaccharide (LPS), TNF-
α,andIL-1stimulatetheproductionofIL-8.Upregulationof
these chemokines in conjunction with polymorphonuclear
cells (PMN) inﬁltration into the inﬂamed intestinal mucosa
correlates well with the degree of active inﬂammation and
tissue injury in human and experimental models of IBD
[78, 150, 151]. CXCR2 is a well-established mediator of
PMN recruitment in preclinical models of inﬂammatory
disease [152–154]. A small molecule CXCR2 antagonist
(SB225002) was eﬀective in ameliorating trinitrobenzene
sulfonic acid- (TNBS-) induced colitis in mice, as was
an anti-CXCL1 antibody [155]. We used bioluminescence
imaging of adoptively transferred luciferase-expressing neu-
trophils to study the kinetics of neutrophil migration in
acute DSS-induced colitis. This enabled demonstration of
preferential recruitment of the neutrophils to the inﬂamed
colon and the blockade eﬀect of an anti-CXCL1 antibody on
the traﬃcking neutrophils [21].
5.4.The“Redundancy”Issue. Thepromiseofdruginhibition
of chemokines and their receptors in IBD has not yet
been realized. The chemokine system is “redundant,” and
the same biological function can be carried out by several
chemokines and their receptors in vivo. This questions their
suitabilityasanti-inﬂammatorydrugtargets.However,itwas
recently pointed out that the lack of progress in chemokine
strategies may not be due to “redundancy,” but rather to the
shortcomings in the approaches employed to target them
[156]. Clinical eﬃcacy of a small molecule CCR9 antagonist
was demonstrated in patients with moderate to severe CD
[157], proving that targeting one chemokine receptor can
be therapeutically successful in the treatment of chronic
inﬂammation.
6. Future Directions: MicroRNAs
Recent studies suggest that microRNAs (miRNAs) play
a speciﬁc role in the posttranscriptional regulation of
leukocyte traﬃcking. miRNAs are small (21−23 nucleotide)
noncoding RNAs that control gene expression. By targeting
complementary messenger RNAs (mRNAs) for degradation
or translational repression, they suppress the expression of
protein-coding genes. Blockade of miR-126 function using
anantagomir,asingle-strandedantisense-likemolecule,sup-
pressed the Th2 response and subsequently the development
of disease in an experimental model of allergic asthma [158].
Interestingly, miR-126 was identiﬁed as one of a set of miR-
NAs expressed in endothelial cells [159, 160] and was shown
to inhibit TNF-induced endothelial expression of VCAM-1,
thus blocking leukocyte adhesion via its lymphocyte integrin
ligand α4β1 [161]. In terms of neutrophil traﬃcking, down-
regulationofE-selectinandICAM-1bymiR-31andmiR-17-
3, respectively, controlled neutrophil binding to endothelial
cells [162]. Inhibition of these miRNAs using speciﬁc
antagonists increased neutrophil adhesion to endothelial
cells in vitro, while transfecting with mimics (agonists) of
these miRNAs had the opposite eﬀect. This study suggests
that miRNAs negatively regulate inﬂammatory processes. In
another study, miR-7 downregulated expression of CD98, a
lymphocyte receptor that regulates integrin signaling [163].
CD98 levelswereincreasedin theinﬂamed colonsof patients
with CD, while miR-7 levels were decreased. Taken together,
the biological importance of miRNAs in the pathogenesis
of IBD is becoming clearer, and targeting miRNAs in the
context of leukocyte traﬃcking may be a safer approach for
future therapeutic opportunities.
7. Concluding Remarks
Targeting leukocyte migration is a realistic strategy, and
Natalizumab shows proof of principle. Compounds inhibit-
ing a single chemokine, such as CCR9, have also shown
promise, but awareness is necessary. Targeting molecules
such as miRNAs, histone deacetylases [164], or the fam-
ily of bromodomain proteins [165], which regulate gene
expression programs that govern endothelial cell function in
inﬂammatory settings, may represent a new generation of
drugs for IBD.
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